A study published in JAMA Network Open analyzed knowledge of hemp-derived cannabinoids such as cannabidiol (CBD), Delta 8-THC, cannabigerol (CBG), and cannabinol (CBN) as well as use to determine the most popular hemp-derived cannabinoids.
The study analyzed a census-representative sample of adults (age 18 and older) from the National Opinion Research Center (NORC) AmeriSpeak panel. 72% of participants reported some knowledge of CBD. Fewer participants had heard of delta-8-THC (41%), CBG (18%), or CBN (17%).
Roughly 21% reported using CBD in the past year. 12% used delta-8-THC, 5% used CBG, and 4% reported consuming CBN. States without legal medical or recreational cannabis demonstrated higher rates of delta-8-THC consumption. These states have a strong market demand for products hemp-derived products containing less than 0.3 percent THC.
The passage of the 2018 Farm Bill removed hemp-derived cannabinoids from the federal Controlled Substances Act. Study author Dr. Kevin Boehnke explained, "While the de-scheduling of hemp products initially opened up the market for CBD products, it also applies to the 100-plus cannabinoids also found in the plant. That means, as with CBD, all of them can follow that same path and be sold in gas stations, as ingredients in cosmetics, as well as in dispensaries—there will likely be substantial proliferation of some of these compounds." Policy loopholes in states without legal cannabis allow for legal access to and use of delta-8-THC, which has similar yet less intense psychoactive effects than THC.
The study highlights the critical need for more rigorous lab testing. Adequate laboratory testing of alternative cannabinoid products' safety and quality can significantly reduce the risks. More thorough testing will screen for pesticides and solvents and require specific amounts listed on the label. Future studies will shed light on reason for consumption, perceptions of safety, and risk and benefits of hemp-derived products.
Sources: Eureka News Alert, JAMA Network Open
